Filing Summary
Business Context and Reporting Period
This Form 8-K was filed by Pono Capital Two, Inc. on September 23, 2022. The filing does not identify SBC Medical Group Holdings Inc. as the registrant; it concerns Pono Capital Two, a special purpose acquisition company. The reported event relates to the trading separation of units issued in the company’s initial public offering.
Key Financial and Capital Markets Information
- Pono Capital Two completed an initial public offering of 11,500,000 units, including 1,500,000 units issued upon full exercise of the underwriters’ over-allotment option.
- Units were sold at $10.00 each, generating gross proceeds of $115.0 million.
- Each unit consists of one share of Class A common stock and one redeemable warrant.
- Each warrant is exercisable for one share of Class A common stock at $11.50 per share, subject to adjustment.
- The filing provides no revenue, profit, cash flow, margin, debt, liquidity, or operating-performance metrics.
Material Changes and Trading Update
Beginning September 26, 2022, holders may elect to separate the shares of Class A common stock and warrants comprising the units. Unseparated units will continue trading on Nasdaq under PTWOU. Separately traded Class A common stock and warrants will trade under PTWO and PTWOW, respectively.
Holders must instruct their brokers to contact Continental Stock Transfer & Trust Company, the transfer agent, to complete the separation.
Guidance, Risks, Contingencies, and Unusual Items
- The filing provides no business guidance, earnings outlook, or management forecast.
- The primary investor consideration is the potential dilution associated with the 11,500,000 redeemable warrants and their $11.50 exercise price.
- The filing does not provide additional information regarding the use of IPO proceeds, a business-combination target, redemption terms, or transaction contingencies.
Investor Verification Checklist
- Verify that the filing relates to Pono Capital Two rather than SBC Medical Group Holdings Inc.
- Confirm the IPO unit count, gross proceeds, warrant terms, and Nasdaq trading symbols.
- Review the company’s IPO registration statement and subsequent filings for trust-account balances, permitted uses of funds, redemption rights, and business-combination deadlines.
- Assess potential dilution from warrants and any later business-combination or sponsor-related disclosures.